Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Operating Leases (2019 - 2025)

Gyre Therapeutics (GYRE) has disclosed Operating Leases for 7 consecutive years, with $539000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 51.04% to $539000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $539000.0, a 51.04% decrease, with the full-year FY2024 number at $885000.0, up 344.72% from a year prior.
  • Operating Leases was $539000.0 for Q3 2025 at Gyre Therapeutics, down from $771000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $1.3 million in Q2 2024 to a low of $121000.0 in Q4 2022.
  • A 5-year average of $668153.8 and a median of $771000.0 in 2025 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: tumbled 70.34% in 2022, then soared 345.71% in 2025.
  • Gyre Therapeutics' Operating Leases stood at $408000.0 in 2021, then crashed by 70.34% to $121000.0 in 2022, then skyrocketed by 64.46% to $199000.0 in 2023, then soared by 344.72% to $885000.0 in 2024, then crashed by 39.1% to $539000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Operating Leases are $539000.0 (Q3 2025), $771000.0 (Q2 2025), and $780000.0 (Q1 2025).